FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

D.C. 20549 OMB APPROVAL

П	OWBALL	V/ \L					
l	OMB Number:	3235-0287					
l	Estimated average burde	n					
ı	hours per response.	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* BROWN MORGAN R						2. Issuer Name and Ticker or Trading Symbol Clene Inc. [CLNN]							5. Relationship of Reporting (Check all applicable) Director			10% Owner	
(Last) (First) (Middle) 6550 SOUTH MILLROCK DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 06/07/2024								Officer (give title Other (specify below) Chief Financial Officer						
```````				4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SALT LA	SALT LAKE UT 84121		84121										Form filed by One Reporting Person  Form filed by More than One Reporting Person				
		(Zip)		Che	Tule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		To	ble I. Nen	Dorivo									, Ournad				
1. Title of Security (Instr. 3)  2. Transa Date (Month/D.				ction 2A. Deemed Execution Date,			3. Transact	Transaction Disposed Of (D) (Instr. 3, 4			ed (A) or	5. Amoun	s F ally (I ollowing (I	Form: (D) or	5. Ownership Form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	/	Amount	ınt (A) or (D)		Transacti (Instr. 3 a	ction(s)			(111511.4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Cod	saction e (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisa Expiration Date (Month/Day/Yea		of Securities		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares		(Instr. 4)			
Stock Options (Right to buy)	\$0.37	06/07/2024		A		400,000		(1)	06	5/06/2034	Common Stock	400,000	\$0.00	400,00	0	D	
Stock Options (Right to buy)	\$0.37	06/07/2024		Α		600,000		(2)	06	5/06/2034	Common Stock	600,000	\$0.00	600,00	0	D	

## **Explanation of Responses:**

1. This option was granted on June 7, 2024 as an option for 400,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of \$0.37 per share. The options vest with respect to the first 25% of such shares on June 7, 2025 and then in 36 equal installments of Common Stock on the 7th day of each calendar month, beginning July 7, 2025, until such shares are fully vested

#### Remarks:

/s/ Jerry Miraglia POA

** Signature of Reporting Person

06/11/2024

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{2.} This option was granted on June 7, 2024 as an option for 600,000 shares of Common Stock under the Clene Inc. Amended 2020 Stock Plan at an exercise price of \$0.37 per share. The options vest with respect to the first 33.3% of such shares if Clene Inc. has an NDA approved by the FDA, and the remaining 33.4% of such shares if Clene Inc. achieves \$100,000,000 in revenues in connection with the sales of any approved drugs.